EG00229
CAS No. 1210945-69-9
EG00229( —— )
Catalog No. M32904 CAS No. 1210945-69-9
EG00229 is a neuropilin 1 (NRP1) receptor antagonist that selectively inhibits the binding of VEGF-A to the NRP1 b1 domain with an IC50 value of 3 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 68 | Get Quote |
|
| 5MG | 96 | Get Quote |
|
| 10MG | 151 | Get Quote |
|
| 25MG | 244 | Get Quote |
|
| 50MG | 361 | Get Quote |
|
| 100MG | 525 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameEG00229
-
NoteResearch use only, not for human use.
-
Brief DescriptionEG00229 is a neuropilin 1 (NRP1) receptor antagonist that selectively inhibits the binding of VEGF-A to the NRP1 b1 domain with an IC50 value of 3 μM.
-
DescriptionEG00229 is a neuropilin 1 (NRP1) receptor antagonist. EG00229 selectively inhibits VEGF-A binding to NRP1 b1 domain with anIC50 of 3 μM, but has no effect on VEGFA binding to VEGFR-1 and VEGFR-2.
-
In VitroEG00229 (Compound 2; 0-100 μM; 48 hours; A549 cells) treatment causes a significant reduction in cell viability over a 48 hours incubation.?EG00229 (Compound 2) demonstrates inhibition of VEGF-A binding to NRP1 and attenuates VEGFR2 phosphorylation in endothelial cells. Inhibition of migration of endothelial cells is also observed in HUVECs.EG00229 (Compound 2) selectively inhibits radiolabeled 125I-VEGF-A binding to porcine aortic endothelial (PAE)/NRP1, but not VEGFR2-expressing cells, with an IC50 of 8 μM. EG00229 also inhibits VEGF-A binding to lung carcinoma A549 and prostate carcinoma DU145 cells, which express NRP1, but not VEGFR1 and VEGFR2, with similar potency. Binding of VEGF-A to human umbilical vein endothelial cells (HUVECs), which express VEGFR2, VEGFR1, and NRP1, is also inhibited by EG00229 with an IC50 of 23 μM.Cell Viability Assay Cell Line:A549 cells Concentration:0 μM, 10 μM, 30 μM, 100 μM Incubation Time:48 hours Result:Caused a significant reduction in cell viability.
-
In VivoEG00229 (0-10 mg/kg; intraperitoneal injection; three times per week; for 4 weeks; NSG mice) treatment substantially reduces tumor growth and visible vascularization.Animal Model:6-week old female NOD scid IL2 receptor gamma chain knockout mice (NSG mice) with ECS cells Dosage:0 mg/kg, 10 mg/kg Administration:Intraperitoneal injection; three times per week; for 4 weeks Result:Reduces tumor growth and visible vascularization.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1210945-69-9
-
Formula Weight611.6
-
Molecular FormulaC19H20F3N7O7S3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 41.4 mg/mL (67.69 mM)
-
SMILESOC(=O)C(F)(F)F.NC(=N)NCCC[C@H](NC(=O)c1sccc1NS(=O)(=O)c1cccc2nsnc12)C(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Jarvis A, et al. Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction. J Med Chem. 2010 Mar 11;53(5):2215-26.?
molnova catalog
related products
-
Lancerin
Lancerin, isolated from the root bark of Cudraniu cochinchinensis, possesses anti-lipid peroxidation.
-
Epipinoresinol-4'-O-...
Epipinoresinol-4'-O-β-D-glucoside (Simplocosin) is a glucoside compound.
-
Eα (52–68)
Eα (52–68)
Cart
sales@molnova.com